Patents by Inventor Edgar Jacoby

Edgar Jacoby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220089568
    Abstract: Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, and R3, are defined herein.
    Type: Application
    Filed: January 10, 2020
    Publication date: March 24, 2022
    Inventors: Justin Cisar, Scott Kuduk, Chao-yuan Wang, Yvan Rene Ferdinand Simonnet, Colleen Elizabeth Keohane, Edgar Jacoby
  • Patent number: 11236084
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: February 1, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: George Hynd, Calum Macleod, Samuel Edward Mann, Janusz Jozef Kulagowski, Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel
  • Patent number: 11186589
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 30, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Patent number: 11180487
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: November 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • Patent number: 11136311
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 5, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Patent number: 11096931
    Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.
    Type: Grant
    Filed: February 21, 2020
    Date of Patent: August 24, 2021
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Stefaan Julien Last, Bart Rudolf Romanie Kesteleyn, Sandrine Céline Grosse, Tim Hugo Maria Jonckers, Jan Martin Berke, Geerwin Yvonne Paul Haché, Edgar Jacoby, Carolina Martinez Lamenca, Morgan Charles R. Lecomte, Abdellah Tahri, Sarah Sauviller, Karen Maria Vergauwen
  • Patent number: 11053248
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: July 6, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Edgar Jacoby, Daniel Oehlrich, Henricus Jacobus Maria Gijsen
  • Publication number: 20210188840
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoinmmune disorders.
    Type: Application
    Filed: July 4, 2018
    Publication date: June 24, 2021
    Inventors: George HYND, Calum MACLEOD, Samuel Edward MANN, Janusz Jozef KULAGOWSKI, Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL
  • Patent number: 11001569
    Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 11, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • Publication number: 20210087182
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: January 20, 2017
    Publication date: March 25, 2021
    Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Virginie Sophie PONCELET, Gerhard Max GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
  • Patent number: 10947242
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: March 16, 2021
    Assignee: Janssen Pharmaceutica, NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Frans Alfons Maria Van den Keybus, Gary John Tresadern, Petrus Jacobus Johannes Antonius Buijnsters, Adriana Ingrid Velter, Edgar Jacoby, Gregor James Macdonald, Henricus Jacobus Maria Gijsen, Abdellah Ahnaou, Wilhelmus Helena Ignatius Maria Drinkenburg
  • Publication number: 20210032267
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: February 6, 2020
    Publication date: February 4, 2021
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Publication number: 20200352925
    Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.
    Type: Application
    Filed: May 5, 2020
    Publication date: November 12, 2020
    Inventors: Bart Rudolf Romanie KESTELEYN, Jan Martin BERKE, Erwin COESEMANS, Sandrine Céline GROSSE, Edgar JACOBY, Tim Hugo Maria JONCKERS, Stefaan Julien LAST, Wim Gaston VERSCHUEREN, Michel OBRINGER, Christelle Catherine Cecile DOEBELIN
  • Publication number: 20200268730
    Abstract: The application relates to amide derivatives, processes for their preparation, pharmaceutical compositions, and their uses, more particularly their uses in treating chronic hepatitis B virus (HBV) infection.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 27, 2020
    Inventors: Stefaan Julien LAST, Bart Rudolf Romanie KESTELEYN, Sandrine Céline GROSSE, Tim Hugo Maria JONCKERS, Jan Martin BERKE, Geerwin Yvonne Paul HACHÉ, Edgar JACOBY, Carolina MARTINEZ LAMENCA, Morgan Charles R. LECOMTE, Abdellah TAHRI
  • Publication number: 20200109129
    Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or disorders.
    Type: Application
    Filed: January 20, 2017
    Publication date: April 9, 2020
    Inventors: Ian STANSFIELD, Olivier Alexis Georges QUEROLLE, Gerhard Mx GROSS, Edgar JACOBY, Lieven MEERPOEL, Janusz Jozef KULAGOWSKI, Calum MACLEOD, Samuel Edward MANN, Simon Richard GREEN, George HYND
  • Publication number: 20200048260
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 13, 2020
    Applicant: Janssen Pharmaceutica NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Petrus Jacobus Johannes Antonius Buijnsters, Gary John Tresadern, Edgar Jacoby, Daniel Oehlrich, Henricus Jacobus Maria Gijsen
  • Publication number: 20190359598
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: June 29, 2017
    Publication date: November 28, 2019
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Publication number: 20190276462
    Abstract: The present invention relates to novel [1,2,4]triazolo[1,5-a]pyrimidin-yl derivatives as inhibitors of phosphodiesterase 2 (PDE2). The invention is also directed to pharmaceutical compositions comprising the compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, such as neurological and psychiatric disorders.
    Type: Application
    Filed: October 31, 2017
    Publication date: September 12, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Yves Emiel Maria Van Roosbroeck, Frans Alfons Maria Van den Keybus, Gary John Tresadern, Petrus Jacobus Johannes Buijnsters, Adriana Ingrid Velter, Edgar JACOBY, Gregor James Macdonald, Henricus Jacobus Maria Gijsen, Abdellah Ahnaou, Wihelmus Helena lgnatius Drinkenburg
  • Publication number: 20190119299
    Abstract: Fused aromatic bicyclic substituted 5-(2-amino-4-pyrimidinyl)-cyanoindoline derivatives (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-KB-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Application
    Filed: June 29, 2017
    Publication date: April 25, 2019
    Applicant: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Publication number: 20170266189
    Abstract: The invention relates to compound of the formula (I); or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.
    Type: Application
    Filed: April 4, 2017
    Publication date: September 21, 2017
    Inventors: Edgar JACOBY, Juergen REINHARDT, Niko SCHMIEDEBERG, Carsten SPANKA